NeoGenomics Pays Off 1.25% Convertible Senior Notes

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology testing services, today announced that it has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes with a maturity date of May 1, 2025, using cash on hand.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250501779949/en/

Investor Contact Kendra Sweeney kendra.sweeney@neogenomics.com

Media Contact Andrea Sampson asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.